DOCSLIB.ORG

Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds Tibotec Data Presented at ICAAC and HIV9 Follow key Regulatory Approvals for Anti-HIV Compounds Not Intended for Journalists in the UK or Ireland New Findings From ARTEMIS and TITAN Studies Demonstrate Growth of the Tibotec Virology Franchise Glasgow, Scotland (November 12, 2008) - New data on PREZISTA® (darunavir), a protease inhibitor from Tibotec, will be presented at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, U.K., from 09-13 November 2008. The company also presented new data on PREZISTA® at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., from 25-28 October 2008. These presentations follow key regulatory approvals and decisions for PREZISTA® and INTELENCE™ (etravirine), a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). The company continues to research various compounds in hepatitis C, tuberculosis and HIV. "The Tibotec data being presented at HIV9 culminate an exciting three months for the company and for the entire HIV community," said Roger Pomerantz, President, Tibotec Research & Development. "The data we've amassed and the regulatory milestones we've achieved this year are signs of our dedication to finding innovative ways to meet the needs of people with HIV." Recent Regulatory Milestones for Tibotec in HIV ● 28 August 2008 - The European Commission approved etravirine, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients. ● 21 October 2008 - The U.S. FDA granted traditional approval to darunavir, coadministered with low dose ritonavir, for twice-daily use in treatment-experienced adult patients, as well as an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naïve adults (those who have never taken HIV medication before). ● 23 October 2008 - Darunavir received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) to extend the drug's indication to treat human immunodeficiency virus (HIV-1) infection to include treatment-experienced adult patients. Darunavir, coadministered with low dose ritonavir, is currently indicated for the treatment of HIV-1 in combination with other antiretroviral medicines in highly pre-treated adult patients who failed more than one regimen containing a protease inhibitor. Tibotec Data at ICAAC and HIV9 Data from multiple studies examining the use of darunavir in patients with varying levels of treatment experience were presented at ICAAC and will be presented at HIV9. Highlights include: ● A new analysis of ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In Naive Subjects), a randomised, controlled, open-label Phase III trial that compares the 96-week efficacy and safety of darunavir/ritonavir with lopinavir/ritonavir in treatment-naive adults. ARTEMIS is the first study to examine darunavir/ritonavir in a once-daily dose in treatment-naive patients with HIV. These data were presented at ICAAC on 26 October. ● A new analysis of TITAN (TMC114/r In Treatment-experienced pAtients Naive to lopinavir), a randomised, controlled, open-label Phase III study that compares the 96-week efficacy and safety of darunavir/ritonavir with lopinavir/ritonavir in treatment-experienced, lopinavir-naive patients. These data will be presented at HIV9 on 13 November. The ARTEMIS and TITAN studies are ongoing. Darunavir and etravirine were developed by Tibotec Pharmaceuticals, Cork, Ireland. Tibotec, a division of Janssen-Cilag, is responsible for marketing the brand in Europe. Please see full Prescribing Information for more details. About Tibotec PharmaceuticalsTibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical research and development company, with offices in Yardley, PA and main research and development operations/labs in Belgium. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need. About Tibotec Tibotec, a division of Janssen-Cilag, will bring innovative products for HIV/AIDS to patients in Europe, the Middle East and Africa This new division was created within the Janssen-Cilag companies in October 2005 to focus on patients' and healthcare providers' specific needs in this disease domain. The company will also commercialise medicine to combat other viral diseases in the future. Janssen-Cilag Janssen-Cilag is a leader in traditional and biological medicines for disorders such as gastroenterology, women's health, mental health and neurology as well as for pain, oncology, haematology and nephrology. (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.).
Load more

Recommended publications
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Nobel Endeavors in Immunology Introducing Dr
    SPRING 2012 A PUBLICATION OF SOUTHWESTERN MEDICAL FOUNDATION Nobel Endeavors in Immunology Introducing Dr. Bruce Beutler, UT Southwestern’s fifth Nobel Laureate, and the new Center for the Genetics of Host Defense Southwestern Medical Foundation Board of Trustees 2011-2012 Edward M. Ackerman Joe M. Haggar, III Richard R. Pollock Sara Melnick Albert Nancy S. Halbreich Caren H. Prothro The Heritage Society Rafael M. Anchia LaQuita C. Hall Carolyn Perot Rathjen OF SOUTHWESTERN MEDICAL FOUNDATION Table of Contents Charlotte Jones Anderson Paul W. Harris* Mike Rawlings table of contents Barry G. Andrews Linda W. Hart Jean W. Roach Joyce T. Alban Mr. and Mrs. Thomas E. McCullough Marilyn H. Augur Joe V. (Jody) Hawn, Jr. Linda Robuck Mr. and Mrs. James R. Alexander Christopher F. McGratty Robert D. Rogers Ralph W. Babb, Jr. Jess T. Hay Anonymous (11) Carmen Crews McCracken McMillan Editor Doris L. Bass Frederick B. Hegi, Jr. Catherine M. Rose George A. Atnip# Ferd C. and Carole W. Meyer Nobel Endeavors in Immunology Peter Beck Jeffrey M. Heller* Billy Rosenthal Marilyn Augur* William R. and Anne E. Montgomery Heidi Harris Cannella The threads of Dr. Bruce Beutler’s scientific 3 # Jill C. Bee Julie K. Hersh Lizzie Horchow Routman* Paul M. Bass* Kay Y. Moran career are inextricably woven into the fabric of W. Robert Beavers, M.D. Barbara and Robert Munford Gil J. Besing Thomas O. Hicks Robert B. Rowling* Creative Director UT Southwestern’s history. From intern to mid-career Drs. Paul R. and Robert H. Munger# Jan Hart Black Sally S. Hoglund Stephen H.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Nda 21-976/S004
    NDA 21-976/S003 - 4 – NDA 21-976/S004 PREZISTA™* (Tibotec, Inc.) (darunavir) Tablets 1. DESCRIPTION PREZISTA™ (darunavir) is an inhibitor of the human immunodeficiency virus (HIV) protease. PREZISTA™ (darunavir), in the form of darunavir ethanolate, has the following chemical name: [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1- (phenylmethyl)propyl]-carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester monoethanolate. Its molecular formula is C27H37N3O7S • C2H5OH and its molecular weight is 593.73. Darunavir ethanolate has the following structural formula: H OO O H OO S H O N N • C2H5OH H H H OH H3C NH2 CH3 Darunavir ethanolate is a white to off-white powder with a solubility of approximately 0.15 mg/mL in water at 20°C. PREZISTA 300 mg and PREZISTA 600 mg tablets are available as orange, oval-shaped, film- coated tablets for oral administration. Each 300 mg tablet contains darunavir ethanolate equivalent to 300 mg of darunavir. Each 600 mg tablet contains darunavir ethanolate equivalent to 600 mg of darunavir. During storage, partial conversion from ethanolate to hydrate may occur; however, this does not affect product quality or performance. Each tablet also contains the inactive ingredients colloidal silicon dioxide, crospovidone, magnesium stearate, and microcrystalline cellulose. The tablet film coating, OPADRY® Orange, contains FD&C Yellow No. 6, polyethylene glycol 3350, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide. All dosages for PREZISTA are expressed in terms of the free form of darunavir. NDA 21-976/S003 - 5 – NDA 21-976/S004 2. MICROBIOLOGY Mechanism of Action Darunavir is an inhibitor of the HIV-1 protease.
    [Show full text]
  • Johnson & Johnson Excluding Special Charges 2002 Second Quarter
    Johnson & Johnson Excluding Special Charges 2002 Second Quarter EPS Rose 17.6% Sales Increased 10.9% New Brunswick, NJ (July 16, 2002) -- Johnson & Johnson today announced record sales of $9.1 billion, an increase of 10.9% over second-quarter 2001 results. Excluding the impact of currency, worldwide sales increased 10.7%. Domestic sales increased 10.7%, while international sales increased 11.3%. Johnson & Johnson also announced net earnings and diluted earnings per share for the second quarter of $1.7 billion and $.54, increases of 11.6% and 12.5% respectively, as compared to the same period in 2001. Excluding special charges related to acquisitions, net earnings and diluted earnings per share were $1.8 billion and $.60, increases of 16.4% and 17.6% respectively, over second-quarter 2001 results. After-tax special charges of $189 million in 2002 include in-process R&D costs associated with the acquisitions of Tibotec-Virco and Obtech Medical AG that were completed during the quarter. The after-tax special charge of $102 million in 2001 was due to one-time costs associated with the ALZA merger. “Our double-digit growth in sales and earnings reflects the broad-based strength of each of our business segments in all geographic regions of the world,”said William C. Weldon, Chairman and Chief Executive Officer. “Of particular note is the strong performance of the worldwide medical devices and diagnostics business as well as the international pharmaceutical and domestic consumer businesses.” Worldwide Pharmaceutical sales of $4.3 billion for the quarter resulted in an increase of 10.2% over the same period in 2001.
    [Show full text]
  • 2016 Annual Report
    ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs.
    [Show full text]
  • Johnson & Johnson Reports First Quarter Increases in Sales and Net
    Johnson & Johnson Reports First Quarter Increases in Sales and Net Earnings New Brunswick, NJ (April 16, 2002) -- Johnson & Johnson today announced sales of $8.7 billion and net earnings of $1.8 billion for the first quarter of 2002, increases of 11.3% and 18.2%, respectively, over first quarter 2001 results. Diluted earnings per share for the first quarter were $.59, up 18.0% from the same period in 2001. Excluding the impact of negative currency, worldwide sales increased 13.4%. Domestic sales were up 17.1%, while international sales increased 8.0% on an operational basis. “I am particularly pleased with the ongoing strength of our Pharmaceutical business and the broad-based growth in the Medical Devices and Diagnostics segment,”said Ralph S. Larsen, Chairman and Chief Executive Officer. Worldwide Pharmaceutical sales of $4.2 billion for the quarter resulted in an operational increase of 21.3% over the same period in 2001. Domestic sales increased 25.6%. International sales increased operationally 12.6% but were partially offset by a negative currency impact of 4.7%. Worldwide reported sales growth including a 1.5% negative currency impact was 19.8%. Sales growth reflects the strong performance of PROCRIT/EPREX, for the treatment of anemia; RISPERDAL, an antipsychotic medication; DURAGESIC, a transdermal patch for chronic pain; REMICADE, a treatment for rheumatoid arthritis and Crohn’s disease; TOPAMAX, an antiepileptic, and ACIPHEX/PARIET, a proton pump inhibitor for gastrointestinal disorders. During the quarter, the Company received U.S. Food and Drug Administration (FDA) approval for RISPERDAL for the additional indication of delaying relapse in the long-term treatment of schizophrenia.
    [Show full text]
  • Gelatina Di K-Y Da Wikipedia, L'enciclopedia Libera Salto A: Navigazione, Ricerca
    Gelatina di K-Y Da Wikipedia, l'enciclopedia libera Salto a: navigazione, ricerca /wiki/Image:K-Y.jpg/wiki/Image:K-Y.jpg /wiki/Image:K-Y.jpgUn tubo della gelatina di K-Y La gelatina di K-Y, anche conosciuta come la gelatina di Panitsa, è un lubrificante personale a base d'acqua e solubile in acqua prodotto da Johnson & Johnson. Le iniziali “K-Y„ non sono conosciute per rappresentare alcune parole - sono state descritte dal loro creatore come “lettere arbitrarie„ - ma sono mantenute per la loro marca- identità. È stato introdotto nel gennaio 1904 dal creatore Van Horn & Sawtell del suturare e farmaceutico di New York City, [1] e più successivamente acquistato da Johnson & Johnson, scopo dichiarato originale della gelatina di K-Y come lubrificante chirurgico ed è stato scelto spesso dai medici a causa della relativa base vegetale. Il prodotto ora è più ampiamente usato come lubrificante sessuale. Non reagisce con i condoms del lattice o il silicone gomma-ha basato i giocattoli del sesso. Mentre non suggerito per ingestione, ha un gusto dello sweetish, in modo da non interferire con il sesso orale. Ha una consistenza spessa e una tendenza asciugarsi durante l'uso, ma può “essere riattivato„ tramite l'aggiunta della saliva o di più acqua. La gelatina di K-Y non contiene uno spermicide. Una formulazione con nonoxynol-9 era disponibile, ma Johnson & Johnson lo ha tirato dal mercato dopo l'individuazione che potrebbe aiutare il HIV a spargersi. [2] Il prodotto può anche essere usato per gli scopi di lubrificazione quando prende la temperatura corporea dal retto.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/27/17 for the Period Ending 01/01/17 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Pharmaceuticals Sector Healthcare Fiscal Year 01/01 http://www.edgar-online.com © Copyright 2017, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 1, 2017 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange New York Stock Exchange 4.75% Notes Due November 2019 New York Stock Exchange 0.250% Notes Due January 2022 New York Stock Exchange 0.650% Notes Due May 2024 New York Stock Exchange 5.50% Notes Due November 2024 New York Stock Exchange 1.150% Notes Due November 2028 New York Stock Exchange 1.650% Notes Due May 2035 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Johnson & Johnson
    9/9/13 Johnson & Johnson - Wikipedia, the free encyclopedia Johnson & Johnson Coordinates: 40°29′55″N 74°26′37″W From Wikipedia, the free encyclopedia Johnson & Johnson is a U.S multinational Johnson & Johnson medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Type Public Average and the company is listed among the Fortune 500. Traded as NYSE: JNJ (http://www.nyse.com/about/listed/lcddata.html? Johnson & Johnson ranked at the top of ticker=jnj) Harris Interactive's National Corporate Dow Jones Industrial Average Component Reputation Survey for seven consecutive S&P 500 Component years up to 2005,[2] was ranked as the world's most respected company by Industry Medical equipment Barron's Magazine in 2008,[3] and was the Pharmaceutical first corporation awarded the Benjamin Founded 1886 Franklin Award for Public Diplomacy by Founder(s) Robert Wood Johnson I, the U.S. State Department in 2005 for its James Wood Johnson, funding of international education programs. Edward Mead Johnson However, in recent years the company's reputation has been adversely affected by Headquarters New Brunswick, New Jersey, United States product recalls, fines for pharmaceutical Area served Worldwide marketing practices, litigation with a group of shareholders, and other legal issues. Key people William Weldon (Chairman of the Board) Johnson & Johnson is headquartered in Alex Gorsky New Brunswick, New Jersey with the (Chief Executive Officer) consumer division being located in Products See list of Johnson & Johnson products Skillman, New Jersey. The corporation includes some 250 subsidiary companies Revenue US$ 65.030 billion (2012)[1] with operations in over 57 countries and Operating US$ 12.361 billion (2012)[1] products sold in over 175 countries.
    [Show full text]
  • 2013 AB 128 Code of Conduct Compliant Companies
    Manufacturers and Wholesalers Street City ST Zip 1109 Spring Holdings, LLC 1109 Spring Managing Member, LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Road Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Point of Care Division Abbott Vascular Division AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Closure, Inc. 645 Clyde Ave. Mountain View CA 94043 Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Actient Pharmaceuticals, LLC 150 S. Sanders Rd. #120 Lake Forest IL 60045 AcuteCare, Inc. Advanced Orthopeadic Solutions, Inc. 336 Beech Ave., unit B6 Torrence CA 90501 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGN Seabreeze, LLC Akrimax Pharmaceuticals, LLC 11 Commerce Drive, 1st Floor Cranford NJ 07016 Alaven Pharmaceuticals, LLC 2260 Northwest parkway Suite A Marietta GA 30067 Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 852 Winter Street Waltham MA 02451 Allen Medical Systems, Inc.
    [Show full text]